<DOC>
	<DOCNO>NCT02312011</DOCNO>
	<brief_summary>This study test safety , tolerability , pharmacokinetics multiple escalate dos ISIS-DMPKRx administer subcutaneously adult patient DM1 .</brief_summary>
	<brief_title>A Safety andTolerability Study Multiple Doses ISIS-DMPKRx Adults With Myotonic Dystrophy Type 1</brief_title>
	<detailed_description>This Phase 1/2a multicenter , blind , placebo-controlled study ISIS-DMPK Rx adult patient DM1 .</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<criteria>1 . Must give write informed consent ( sign date ) authorization require local law able comply study requirement 2 . Males female age 20 55 year old time inform consent 3 . Satisfy follow : 1 . Females : nonpregnant nonlactating , surgically sterile , post menopausal , abstinent , engage sexual relation childbearing potential , subject use acceptable contraceptive method time sign informed consent least 14 week last dose Study Drug . 2 . Males : surgically sterile , abstinent engage sexual relation female childbearing potential , subject must use acceptable contraceptive method time sign informed consent form least 14 week last dose Study Drug . 4 . BMI &lt; 35.0 kg/m2 5 . Genetic confirmation DM1 DMPK CTG repeat length â‰¥ 100 6 . Onset DM1 symptom age 12 7 . Clinically apparent myotonia equivalent hand open time least 2 second , opinion Investigator 8 . Ambulatory ( orthoses allow , cane walker allow ) able walk least 25 meter screen 1 . Clinically significant abnormality medical history ( e.g. , previous acute coronary syndrome within 6 month screen , major surgery within 3 month screen ) physical examination 2 . Clinically significant abnormality screen laboratory value would render subject unsuitable inclusion 3 . Active infection require systemic antiviral antimicrobial therapy complete prior Study Day 1 4 . Unwilling unable comply study procedure ( e.g. , muscle biopsy ) , include followup , specify protocol , unwillingness cooperate fully Investigator 5 . Known history previous positive test human immunodeficiency virus ( HIV ) , hepatitis C , chronic hepatitis B 6 . Active malignancy history within last 5 year , except basal squamous cell carcinoma skin , carcinoma situ cervix successfully treat , pilomatricoma 7 . Treatment another investigational drug , biologic agent , device within one month screening , 5 halflives investigational agent , whichever longer ; history previous treatment oligonucleotide ( include siRNA ) 8 . Recent history current drug alcohol abuse 9 . History bleed tendency ongoing oral anticoagulation 10 . Developmental delay , intellectual disability , significant behavioral neuropsychiatric manifestation 11 . Thyroid dysfunction untreated ( thyroid hormone replacement therapy , need adequate stable replacement previous 6 month ) 12 . Implanted device treatment cardiac problem ( i.e. , pacemaker defibrillator ) 13 . Clinically significant abnormal ECG echocardiogram , significant symptom cardiac dysfunction Screening 14 . Have seizure disorder 15 . If treat testosterone , stable replacement dose ( i.e. , hypogonadism ) 16 . Treatment corticosteroid within 8 week prior first dose Study Drug 17 . History hypersensitivity local anesthetic use biopsy procedure component thereof 18 . Treatment antimyotonia medication within 30 day prior screen . May include , limited : Phenytoin , Carbamazepine , Procainamide , Disopyramide , Nifedipine , Acetazolamide , Clomipramine , Imipramine , Amytriptiline , Taurine , Quinine , Mexiletine 19 . Have condition , , opinion investigator would make subject unsuitable inclusion , could interfere subject participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myotonic Dystrophy</keyword>
	<keyword>DM1</keyword>
	<keyword>Adult onset</keyword>
	<keyword>Neuromuscular Disease</keyword>
	<keyword>DMPKRx</keyword>
</DOC>